PMID- 27713136
OWN - NLM
STAT- MEDLINE
DCOM- 20180305
LR  - 20220317
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 8
IP  - 2
DP  - 2017 Jan 10
TI  - The role of extracellular vesicles in mediating progression, metastasis and 
      potential treatment of hepatocellular carcinoma.
PG  - 3683-3695
LID - 10.18632/oncotarget.12465 [doi]
AB  - Hepatocellular carcinoma (HCC) is a major cause of cancer-related death 
      worldwide. As vectors for intercellular information exchange, the potential role 
      of extracellular vesicles (EVs) in HCC formation, progression and therapy has 
      been widely investigated. In this review, we explore the current status of the 
      researches in this field. Altogether there is undeniable evidence that EVs play a 
      crucial role in HCC development, metastasis. Moreover, EVs have shown great 
      potential as drug delivery systems (DDSs) for the treatment of HCC. Exosomal 
      miRNAs derived from HCC cells can enhance transformed cell growth in recipient 
      cells by modulating the expression of transforming growth factor-beta activated 
      kinase-1(TAK1) and downstream signaling molecules. Furthermore, vacuolar protein 
      sortin 4 homolog A(VPS4A) and insulin-like growth factor(IGF)-1 regulate 
      exosome-mediated miRNAs transfer. Immune cells- derived EVs containing integrin 
      alphaMbeta2 or CD147 may facilitate HCC metastasis. In addition, EVs-mediated shuttle of 
      long non-coding RNAs (lncRNAs), specifically linc- VLDLR and linc-ROR promote 
      chemoresistance of malignant cells. Heat shock proteins (HSPs)-harboring exosomes 
      derived from HCC tumor cells increase the antitumor effect of natural killer (NK) 
      cells, thus enhancing HCC immunotherapy. Indeed, inhibition of HCC tumor growth 
      has been associated with tumor cell-derived exosomes (TEX)-pulsed dentritic cells 
      (DCs). Exosomes are also essential in liver metastasis during colorectal 
      carcinoma (CRC) and pancreatic ductal adenocarcinomas (PDAC). Therefore, as 
      nucleic acid and drug delivery vehicles, EVs show a tremendous potential for 
      effective treatment against HCC.
FAU - Yang, Naibin
AU  - Yang N
AD  - Department of Infection and Liver Diseases, Ningbo First Hospital, Ningbo, China.
FAU - Li, Shanshan
AU  - Li S
AD  - Department of Infection and Liver Diseases, The First Affiliated Hospital of 
      Wenzhou Medical University, Institute of Liver Research, Wenzhou Medical 
      University, Wenzhou, China.
FAU - Li, Guoxiang
AU  - Li G
AD  - Department of Infection and Liver Diseases, Ningbo First Hospital, Ningbo, China.
FAU - Zhang, Shengguo
AU  - Zhang S
AD  - Department of Infection and Liver Diseases, The First Affiliated Hospital of 
      Wenzhou Medical University, Institute of Liver Research, Wenzhou Medical 
      University, Wenzhou, China.
FAU - Tang, Xinyue
AU  - Tang X
AD  - Department of Infection and Liver Diseases, The First Affiliated Hospital of 
      Wenzhou Medical University, Institute of Liver Research, Wenzhou Medical 
      University, Wenzhou, China.
FAU - Ni, Shunlan
AU  - Ni S
AD  - Department of Infection and Liver Diseases, The First Affiliated Hospital of 
      Wenzhou Medical University, Institute of Liver Research, Wenzhou Medical 
      University, Wenzhou, China.
FAU - Jian, Xiaomin
AU  - Jian X
AD  - Department of The First Clinical Medical, Wenzhou Medical University, Wenzhou, 
      China.
FAU - Xu, Cunlai
AU  - Xu C
AD  - Department of Respiration, Lishui People's Hospital of Wenzhou Medical 
      University, Lishui, China.
FAU - Zhu, Jiayin
AU  - Zhu J
AD  - Laboratory Animal Center, Wenzhou Medical University, Wenzhou, China.
FAU - Lu, Mingqin
AU  - Lu M
AD  - Department of Infection and Liver Diseases, The First Affiliated Hospital of 
      Wenzhou Medical University, Institute of Liver Research, Wenzhou Medical 
      University, Wenzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Carcinoma, Hepatocellular/genetics/*metabolism/*pathology/therapy
MH  - Cell-Derived Microparticles/metabolism
MH  - Cholangiocarcinoma
MH  - Disease Progression
MH  - Drug Delivery Systems
MH  - Drug Resistance, Neoplasm
MH  - Exosomes/*metabolism
MH  - Extracellular Vesicles/*metabolism
MH  - Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Immunotherapy
MH  - Liver Neoplasms/genetics/*metabolism/*pathology/therapy
MH  - Mesenchymal Stem Cell Transplantation
MH  - Mesenchymal Stem Cells/cytology/metabolism
MH  - Neoplasm Metastasis
MH  - Signal Transduction
PMC - PMC5356911
OTO - NOTNLM
OT  - MSCs
OT  - exosomes
OT  - extracellular vesicles
OT  - hepatocellular carcinoma
OT  - miRNA
COIS- CONFLICTS OF INTEREST The authors declare no conflict of interests.
EDAT- 2016/10/08 06:00
MHDA- 2018/03/06 06:00
PMCR- 2017/01/10
CRDT- 2016/10/08 06:00
PHST- 2016/04/28 00:00 [received]
PHST- 2016/09/28 00:00 [accepted]
PHST- 2016/10/08 06:00 [pubmed]
PHST- 2018/03/06 06:00 [medline]
PHST- 2016/10/08 06:00 [entrez]
PHST- 2017/01/10 00:00 [pmc-release]
AID - 12465 [pii]
AID - 10.18632/oncotarget.12465 [doi]
PST - ppublish
SO  - Oncotarget. 2017 Jan 10;8(2):3683-3695. doi: 10.18632/oncotarget.12465.